326 results about "SCLC - Small cell lung cancer" patented technology

The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.

The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.

The invention relates to a gemcitabine hydrochloride lyophilized powder injection and a preparation method thereof. The gemcitabine hydrochloride lyophilized powder injection prepared by the method can be used as a therapeutic medicament for treating middle and late non-small cell lung cancer, pancreatic cancer and the like. The gemcitabine hydrochloride lyophilized powder injection is characterized by consisting of gemcitabine hydrochloride, mannitol and sodium acetate, wherein the weight ratio of the gemcitabine hydrochloride to the mannitol is 1:0.5-5, and the weight ratio of the gemcitabine hydrochloride to the sodium acetate is 1:0.01-0.1. The preparation method comprises the following steps: taking the mannitol and the sodium acetate; dissolving the mannitol and the sodium acetate by adding injection water; adding the gemcitabine hydrochloride to the mixture, stirring and dissolving the mixture, and adjusting the pH to between 2.7 and 3.3; fixing the volume; filtering the product by a 0.22 mu m microporous membrane; filling, dishing up, lyophilizing, and compressing; taking the product out of a box, and tying the product with an aluminum-plastic composite cover; and inspecting the quality, and packaging the product after passing the quality inspection to obtain the gemcitabine hydrochloride lyophilized powder injection.

In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

The present invention provides methods for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer comprising periodically administering to the human patient chemotherapy comprising an amount of docetaxel; and 640 mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2′-O-methoxyethyl modifications, has nucleotides 5-17 which are 2′deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, thereby treating the human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer. The present invention also provides compositions and combinations, packages, and uses thereof for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.

Belonging to the field of biotechnology, the invention discloses a non-small cell lung cancer (NSCLC) marker, which is STAT3, and also can include CEA, CA125 and CYFRA21-1. The invention confirms the high expression of STAT3 in peripheral blood and serum, and discloses application of STAT3 in preparation of NSCLC diagnostic reagents by the inventor. Specifically, by making use of a genetic recombination technology and targeting at the gene coding region of STAT3, an eukaryotic expression vector PSUPER-STAT3 able to transcribe in vivo and generate small interference RNA (siRNA) is constructed successfully, and is transfected into an eukaryotic cell, thus laying a foundation for a further experimental study on lung cancer RNAi (RNA interference) and antitumor gene therapy. Utilization of the RNAi technology can effectively inhibit the gene expression of STAT3, induce cell apoptosis, and establish the base for molecular mechanism research and gene therapy of lung cancer, thus providing application of the marker provided in the invention in preparing related targeted medicines.

The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention. The compound of the present invention can be used as a pharmaceutical composition for preventing and / or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive and / or mutant EGFR polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive and / or mutant EGFR polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive and / or mutant EGFR polynucleotide-positive non-small cell lung cancer, etc.

The invention discloses aptamer for typing different subtypes of non-small cell lung cancer and a method for screening the same. The aptamer provided by the invention is any DNA segment of nucleotide expressed by sequence 1 to sequence 9 in a sequence table. The aptamer is applied for typing different subtypes of non-small cell lung cancer. The aptamer of the invention can differentiate the different subtypes of non-small cell lung cancer on the molecule response signal under the condition of not knowing tumor markers of the non-small cell lung cancer. Using the aptamer of the invention for identifying the combined target is good for discovering the tumor markers of the different subtypes of non-small cell lung cancer, and earlier and exactly diagnosing and typing non-small cell lung cancer and discovering the tumor for treating new drug action targets.

The invention discloses an electrochemical immunoassay method based on Au-PB-SiO2 composite nano-particles. The detection method adopts a double antibody sandwich method, allows neuron-specific enolase antibodies solid-supported on an electrode surface to perform an immunoreaction with neuron-specific enolase in a sample solution, and to combine with a co-coupled substance of Au-PB-SiO2 composite nano-particles and neuron-specific enolase antibodies. Based on the electrochemical activity of Au-PB-SiO2 composite nano-particles, the detected peak current value of a cyclic voltammetry reduction peak is positively correlated with the concentration of the neuron-specific enolase, and thus the concentration of the neuron-specific enolase in the sample to be detected can be detected. The electrochemical immunoassay method provided by the invention has a corresponding linear range of 0.25-500 ng / ml, and a lower detection limit of 0.08 ng / ml, has good specificity and high sensitivity, and has important significance for the diagnosis of small cell lung cancer (SCLC).

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg / kg to 18 mg / kg, preferably 8 to 12 mg / kg, more preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

The invention discloses a tumor homing cell-penetrating peptide tLyP-1 modified apoferritin nano-cage and a preparation method thereof. The protein nano-cage is hollow cage-shaped protein formed by self-assembling 24 protein subunits; and one tumor homing cell-penetrating peptide tLyP-1 is modified on an N end of each protein subunit by utilizing a gene recombination technology to obtain a recombinant human body heavy-chain ferritin nano-cage with a tLyP-1 modified surface. According to the protein nano-cage provided by the invention, a medicine is loaded into the nano-cage through adjusting depolymerization and recombination of the protein subunits; the nano-cage has good water solubility and biocompatibility, has excellent stability in a human body and has a uniform size; the nano-cage can be specifically combined with a lot of neuropilin receptors 1 (NRP-1) which are expressed in tumor neovascularization and tumor cells of malignant tumors including gliomas, breast cancer, pancreatic cancer, gastric cancer, colorectal cancer, non-small cell lung cancer and the like; and types of the tumors treated by the nano-cage are greatly increased and the targeting ability of tumor treatment is improved. The protein nano-cage provided by the invention has an extremely great application prospect in the aspects of tumor diagnosis and treatment and the like.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum / blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

The invention discloses an NSCLC (non-small cell lung cancer) detection kit and an application thereof. The NSCLC detection kit comprises substances for detecting the content of 9 miRNAs (miRNA-hsa-miR-20a, hsa-miR-25, hsa-miR-223, hsa-miR-320, hsa-miR-222, hsa-miR-146a, hsa-miR-191, hsa-miR-24 and hsa-miR-130a), CEA and CYFRA21-1. The kit can be used for well screening NSCLC and is high in sensitivity, high in specificity and suitable for screening of NSCLC, particularly for NSCLC at the early stage. Therefore, early warning can be given for the lung cancer risk of people by use of the 9 miRNAs in combination with the CEA and CYFRA21-1, and the early diagnosis proportion can be increased.

The described invention provides pharmaceutical compositions, systems and methods for treating a non-small cell lung cancer (NSCLC) solid tumor comprising a population of tumor cells. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein therapeutic amount of the polypeptide is effective to inhibit a kinase activity in the population of tumor cells and to reduce cancer cell proliferation, to reduce tumor size, to reduce tumor burden, to induce tumor cell death, to overcome tumor chemoresistance, to enhance tumor chemosensitivity, or a combination thereof.

The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.

The invention relates to substituted benzamide compounds shown as a general formula (I) or medicinal salts thereof, preparation of the compounds or the medicinal salts thereof, a medicament composition containing the compounds or the medicinal salts thereof and application of the compounds in treatment of cancers, in particular application in treatment of head and neck cancers, non-small cell lung cancer, pancreatic cancer, colorectal cancer, bladder cancer, breast cancer, ovarian cancer and flat cell cancer and application in medicaments for treating the cancers.

The invention provides a novel viral vaccine for treating a non-small cell lung cancer and a preparation method thereof. The preparation method of the viral vaccine comprises the first step of constructing a carrier of an MVA virus and the second step of obtaining specificity presenting MAGE-3 antigen DC cells. According to the viral vaccine prepared through the method, the biological stability is high, adverse effects on human bodies are not produced, and pathogenic dangers do not exist; a virus antibody can obtain a large number of viral particles with high purity easily; MAGE-A3 expressed by the viral vaccine has better immunogenicity, more epitopes are achieved, and drug resistance is not prone to being caused; the viral load needed in inoculation of the viral vaccine is smaller than other viruses.

The present invention relates generally to methods and kits for detecting one or more biomarkers, such as an Epidermal Growth Factor Receptor (EGFR) mutation, e.g., T790M mutation, L858R mutation, one or more exon19 insertions and / or one or more exon19 deletions in the EGFR gene, in a biological sample to aid in diagnosis, prognosis, monitoring, or therapy selection for a disease such as, for example, cancer. The methods and kits are useful in aiding in diagnosis, prognosis, monitoring, or therapy selection for lung cancer, e.g., non-small cell lung cancer (NSCLC).

This present invention compositions and methods of treating, diagnosing, prognosing cancer and methods of accessing / monitoring the responsiveness of a cancer cell to a therapeutic compound.

The invention relates to the field of computers, in particular to a method for analyzing the proportion of PD-L1 positive tumor cells in non-small cell lung cancer and storage equipment. The method for analyzing the proportion of the PD-L1 positive tumor cells in the non-small cell lung cancer comprises the following steps: acquiring a section to be dyed; carrying out immunohistochemical stainingoperation on a tumor cell marker; carrying out immunohistochemical staining operation on a specific marker; obtaining a first region of interest, obtaining feature points, and calculating the total number of tumor cells according to the number of the feature points; obtaining feature points according to a second region of interest, and calculating the number of tumor cells stained by the specificmarker according to the feature points; and calculating the positive proportion fraction of the tumor cells according to the total number of the tumor cells and the number of the tumor cells dyed by the specific marker. In the whole process, a pathologist does not need to perform manual interpretation, so that the obtained result is more accurate and objective, and the efficiency is higher.

The invention relates to a binary classification method for processing non-small cell lung cancer data with missing values and imbalance, and belongs to the technical field of data classification. Themethod comprises the following steps: preprocessing data, filling missing values with medians, eliminating abnormal values by using a Tukey's method, and normalizing the data by using deviation standardization; secondly, carrying out data balance by adopting an SMOTEENN comprehensive sampling method combining oversampling and undersampling; finally, the balanced data set is used for training a random forest classifier, the classification effect is tested on the test set, and therefore the non-small cell lung cancer survival prediction dichotomy method effectively aiming at the problems of missing values and class imbalance is achieved. Experiments performed on a non-small cell lung cancer data set prove the effectiveness and superiority of the method, the classification precision of the non-small cell lung cancer data with missing values and imbalance is improved, and more accurate medical decisions can be achieved.

The invention discloses a method for treating malignant tumors with joint medicament administration and also discloses an anti-malignant tumor medicinal composition with an antitumor activity and a low toxicity and an anti-malignant tumor medicinal preparation using the medicinal composition as an active component. The method comprises a step of jointing administrating anti-inflammatory medicaments, such as glucocorticosteroids or immunosuppressive agents or biotic agents of target cell factors and a carboxamidotriazole or derivatives or intermediates of the carboxamidotriazole as a medicamentto treat malignant tumors, wherein the anti-inflammatory medicaments have a certain regulation effect on cell factors. Tests prove that the combined medicament can increase the sensitivity of tumor cells to the carboxamidotriazole, so the combined medicament can be used as a broad-spectrum medicament for treating a plurality of malignant tumors, particularly non-small cell lung cancer, colon cancer and the like.

The invention belongs to the technical field of immunotherapy prognosis, and in particular relates to a method for immunotherapy prognosis of non-small cell lung cancer (NSCLC) patients. The method uses a gene NFE2L2 and / or KEAP1 as a biomarker, whether the biomarker is mutated or not is detected, and thereby the prognosis of the sensitivity of NSCLC patients to immunotherapy, especially immunotherapy with immune checkpoint inhibitors (ICIs) is performed. In addition, the invention also provides a kit including biomarker detection reagents and an application of the kit. The method or the kit of the invention can be used to accurately predict the population sensitive to ICIs immunotherapy among NSCLC patients with NFE2L2 and / or KEAP1 mutations, and thereby the effectiveness and clinical benefit of immunotherapy for such patients are improved.

The invention discloses a non-small cell lung cancer pathological section identification method based on a deep convolutional neural network. The method comprises the following steps: acquiring pathological sections of non-small cell lung cancer in a public data set from TCGA; constructing a deep learning model for training; inputting the training data set into a convolutional neural network for training to obtain a learned convolutional neural network model; and inputting the training data set into a convolutional neural network for training to obtain a learned convolutional neural network model. According to the method, the Inception-v3 model and the CBAM attention mechanism are fused together, so that the classification of the non-small cell lung cancer is realized, and the network precision is improved through the attention mechanism; meanwhile, a deep convolutional neural network Inception-v3 experimental result shows that the non-small cell lung cancer pathological section identification method based on deep learning provided by the invention can effectively classify lung adenocarcinoma and lung squamous cell carcinoma, reduces the burden of doctors to a certain extent, and realizes very good performance in the field of medical image identification.

The invention discloses application of a serum molecular marker combination as a lung cancer diagnosis and curative effect monitoring marker, belonging to the field of immunodetection. The content of protein (OPN, SAA, CRP, CEA, CYFRA21.1, MIF, AGP, HGF, E-selectin, GRO and NSE) in 11 serums is measured through a Luminex protein chip diagnosis technology. The eight serum protein molecular markers are OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF. The eight serum protein molecular markers have significant promotion effect on a non-small cell lung cancer (NSCLC) and a small cell lung cancer (SCLC). A three-protein detection combination formed by OPN, CEA and another protein (CRP, SAA, CYFRA21.1 or NSE) has excellent diagnosis potential on NSCLC. Compared with the prior art, the serum molecular marker combination has the beneficial effects that the content of multiple protein molecular markers of serum of a patient with lung cancer is detected, and the serum molecular marker combination can be used for lung cancer diagnosis and curative effect monitoring through coordinated comparative analysis of the multiple protein molecular markers.

The invention discloses application of miR-340 as a marker of detecting non-small-cell lung cancer metastasis, or as a marker of pre-judging the risk of non-small-cell lung cancer metastasis, or as a drug resistance marker for non-small-cell lung cancer. It is discovered that the miR-340 can target at downregulation of the expression level of death-associated protein kinase, the death-associated protein kinase being closely related to the metastasis and drug resistance of non-small-cell lung cancer. The increase in expression of the miR-340 indicates the increase in the chances of non-small-cell lung cancer metastasis, causing drug resistance and bad prognosis. On this basis, the moiR-340 can also serve as a target for inhibiting / preventing non-small-cell lung cancer adhesion or attack or inhibiting / preventing non-small-cell lung cancer drug resistance and can also be further popularized and applied to the prevention, treatment and prognosis of other tumor cells. The miR-340 is a new diagnostic tool provided for the clinical molecular-level diagnosis of non-small-cell lung cancer metastasis and drug resistance, and a new drug target is provided for the genetic therapy of non-small-cell lung cancer metastasis.

The invention relates to a diarylpyrimidine compound, a composition and application. The diarylpyrimidine compound is particularly a compound as shown in a general formula (I), and all substituent groups of the general formula (I) are as defined in the description. The invention further relates to application of the compound as shown in the general formula (I) or a pharmaceutically acceptable salt or the pharmaceutical composition in treating tumor diseases, particularly treating a non-small cell lung cancer, a small cell lung cancer, squamous-cell carcinoma, a breast cancer and lymphocytic leukemia by inhibiting epidermal growth factor receptor (EGFR) protein tyrosine kinase (PTK). Please see the formula in the description.

The invention discloses a targeted protein degradation c-Met degradation agent as well as a preparation method and application thereof. The invention provides a c-Met degradation agent based on a targeted protein degradation PROTAC strategy, a preparation method thereof and application of the c-Met degradation agent in the treatment of non-small cell lung cancer, gastric cancer and other cancers.The compound has a remarkable c-Met degradation effect and a remarkable cell proliferation inhibition effect, has the potential of serving as an anti-tumor drug to treat tumors, shows remarkable proliferation inhibition activity in an EBC1 drug-resistant cell strain constructed by lentiviral transfection, is obviously superior to a small molecule inhibitor LXM262. and obviously improves the cell selectivity. The compound has significant advantages in overcoming tumor c-Met acquired drug resistance, especially the compound S27 only provides good activity for c-Met dependent EBC-1 lung cancer cells, it is indicated that the compound S27 has good cell selectivity while the original small molecule inhibitor is multi-target, and the compound also has an inhibition effect on a c-Met non-dependent cell line.

The invention relates generally to the field of cancer detection, diagnosis, subtyping, staging, prognosis, treatment and prevention. More particularly, the present invention relates to methods for the detection, and / or diagnosing and / or subtyping and / or staging of lung cancer in a patient. Based on a particular panel of biomarkers, the present invention provides methods to detect, diagnose at an early stage and / or differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) and within NSCLC to differentiate between squamous cell carcinomas (SCC), adenocarcinomas (AC), within SCC to discriminate G2 and G3 stage and within lung cancer to differentiate for lung cancers with or without neuroendocrine origin. It further provides the use of said panel of biomarkers in monitoring disease progression in a patient, including both in vitro and in vivo imaging techniques. The in vitro imaging techniques typically include an immunoassay detecting protein or antibody of the biomarkers on a sample taken from said patient, e.g. serum or tissue sample. The in vivo imaging techniques typically include chest radiographs (X-rays), Computed Tomography (CT) imaging, spiral CT, Positron Emission Tomography (PET), PET-CT and scintigraphy for molecular imaging and diagnosis and to monitor disease progression and treatment response in patients. It is accordingly a further aspect to provide a kit to perform the aforementioned diagnosing and / or subtyping and / or staging assay and the imaging techniques, comprising reagents to determine the gene expression or protein level of the aforementioned panel of biomarkers for in vitro and in vivo applications.